Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
By M. Bookman, M. Brady, W. Mcguire, P. Harper, D. Alberts, M. Friedlander, N. Colombo, J. Fowler, P. Argenta, K. De Geest and 6 more. Journal of Clinical Oncology, 2009
696 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/cec6767c0a50da65be165cbf97898526294453bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Obstetrics and Gynecology
In Reproductive Medicine
Citations in the corpus
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “This has been the standard treatment of more than 15 years, and clinical trials in the last decade adding a third drug, such as the large Gynaecologic Cancer InterGroup (GCIG) ICON-5/GOG 182 trial [39], have not been shown to improve PFS or OS in these patients.”
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, neutral): “8 months) for any of the experimental regimens compared with carboplatin/ paclitaxel.(74) Some controversy exists regarding the appropriate doses of carboplatin and paclitaxel to use in this setting.”
- A phase 3 trial of bevacizumab in ovarian cancer. (2011, neutral): “Any thromboembolic event None 708 (94) 665 (89) Grade 1 or 2 22 (3) 29 (4) Grade ≥3 23 (3) 51 (7) Venous thromboembolic event None 722 (96) 695 (93) Grade 1 or 2 18 (2) 18 (2) Grade ≥3 13 (2) 32 (4) Arterial thromboembolic event None 742 (99) 718 (96) Grade 1 or 2 1 (<1) 7 (1) Grade ≥3 10 (1) 20 (3)”